Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
作者： F Di Fiore , R Sesboüé , P Michel , J C Sabourin , T Frebourg
关键词:
摘要: … EGFR activation is oncogenic, as predicted by cellular and animal models, the molecular mechanisms underlying EGFR activation in colorectal cancer … IHC and FISH analyses are the …
nature.com
bpa-pathology.com参考文章(56)
G. I Meling, P Laurent-Puig, B. J Iacopetta, R Glaesener, O. P. F Clausen, F Al-Mulla, W Giaretti, V. J Bubb, A. F. P. M de Goeij, G Gaudernack, T Ohkusa, P Quirke, A Rapallo, N Hawkins, R Rosell, T. O Rognum, S. N Andersen, R Smith, J Costa, R Ward, I Hoffmann, T Fujimori, D Cunningham, D Morton, C. T Croke, J Oates, X. F Sun, S Bell, P. A Clarke, S. T Wang, J Breivik, O Muller, A. R Norman, J. W Arends, M Pauly, D Dillon, H. J. N Andreyev, S. D Finkelstein, A. J Senagore, C. N Hall, K Wilkinson, N Lees, N. R Cruickshank, H. S Goh, D Snary, E Jullian, C Valavanis, L Losi, A Russo, H. M Rabes, J Piris, S Wadler, Y Ono, T Azuma, A Font, C Zietz, M Beranek, J. C Fox, S. A Halter, R Benamouzig, B. R Dix, H Zhang, C Faber, K Omura, V. E Pricolo, C Troungos, K Krtolica, J Benhattar, J. W. C Ho, N. Urosevic, T Lovig, D. P O'Donoghue, J. S Thebo, P De Angelis, J. Q Lee, J Young, Bazan, P Jandik, S Olschwang, S. T Yuen, T Walsh, S Malik, M Tanaka, Kirsten ras mutations in patients with colorectal cancer : the ‘RASCAL II’ study Faculty of Health; Institute of Health and Biomedical Innovation. ,vol. 85, pp. 692- 696 ,(2001)
Jan Pander, Hans Gelderblom, Ninja F. Antonini, Jolien Tol, Johan H.J.M. van Krieken, Tahar van der Straaten, Cornelis J.A. Punt, Henk-Jan Guchelaar, Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. European Journal of Cancer. ,vol. 46, pp. 1829- 1834 ,(2010) , 10.1016/J.EJCA.2010.03.017
Nicola Personeni, Steffen Fieuws, Hubert Piessevaux, Gert De Hertogh, Jef De Schutter, Bart Biesmans, Wendy De Roock, An Capoen, Maria Debiec-Rychter, Jean-Luc Van Laethem, Marc Peeters, Yves Humblet, Eric Van Cutsem, Sabine Tejpar, Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab : A fluorescent in situ hybridization study Clinical Cancer Research. ,vol. 14, pp. 5869- 5876 ,(2008) , 10.1158/1078-0432.CCR-08-0449
F Di Fiore, F Blanchard, F Charbonnier, F Le Pessot, A Lamy, M P Galais, L Bastit, A Killian, R Sesboüé, J J Tuech, A M Queuniet, B Paillot, J C Sabourin, F Michot, P Michel, T Frebourg, Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. British Journal of Cancer. ,vol. 96, pp. 1166- 1169 ,(2007) , 10.1038/SJ.BJC.6603685
Mario Scartozzi, Italo Bearzi, Alessandra Mandolesi, Chiara Pierantoni, Fotios Loupakis, Alberto Zaniboni, Francesca Negri, Antonello Quadri, Fausto Zorzi, Eva Galizia, Rossana Berardi, Tommasina Biscotti, Roberto Labianca, Gianluca Masi, Alfredo Falcone, Stefano Cascinu, Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis. BMC Cancer. ,vol. 9, pp. 303- 303 ,(2009) , 10.1186/1471-2407-9-303
F Di Fiore, F Charbonnier, B Lefebure, M Laurent, F Le Pessot, P Michel, T Frebourg, Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer. British Journal of Cancer. ,vol. 99, pp. 551- 552 ,(2008) , 10.1038/SJ.BJC.6604451
Hans Prenen, Jef De Schutter, Bart Jacobs, Wendy De Roock, Bart Biesmans, Bart Claes, Diether Lambrechts, Eric Van Cutsem, Sabine Tejpar, PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clinical Cancer Research. ,vol. 15, pp. 3184- 3188 ,(2009) , 10.1158/1078-0432.CCR-08-2961
F Molinari, V Martin, P Saletti, S De Dosso, A Spitale, A Camponovo, A Bordoni, S Crippa, L Mazzucchelli, M Frattini, Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. British Journal of Cancer. ,vol. 100, pp. 1087- 1094 ,(2009) , 10.1038/SJ.BJC.6604848
Alejo Efeyan, Manuel Serrano, p53: guardian of the genome and policeman of the oncogenes. Cell Cycle. ,vol. 6, pp. 1006- 1010 ,(2007) , 10.4161/CC.6.9.4211
J. Douillard, S. Siena, J. Cassidy, J. Tabernero, R. Burkes, M.E. Barugel, Y. Humblet, D. Cunningham, M. Wolf, J.L. Gansert, 10LBA Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial Ejc Supplements. ,vol. 7, pp. 6- ,(2009) , 10.1016/S1359-6349(09)72039-7